“Lebrikizumab Provides Stable Itch Response With No or Minimal Fluctuations up to One Year in Patients With Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine 7, no. 6 (November 13, 2023): s282. Accessed April 19, 2026. https://skin.dermsquared.com/skin/article/view/2390.